ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
MicroRNA 130b enhances drug resistance in human ovarian cancer cells.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 54 citations in OpenAlex.
- The expression of exosomal and cellular miRNAs in predicting oxaliplatin resistance in colorectal cancer cells: an in silico and in vitro study.BMC cancer · 2025Article
- Emerging role of miRNAs in the regulation of ferroptosis.Frontiers in molecular biosciences · 2023Review
- Glutathione Transferase P1: Potential Therapeutic Target in Ovarian Cancer.Medicina (Kaunas, Lithuania) · 2022Review
- Differences of time-dependent microRNA expressions in breast cancer cells.Non-coding RNA research · 2021Article
- Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression.Cell death & disease · 2020Review
- Review
- Therapeutic microRNAs in human cancer.Cytotechnology · 2019Review
- Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer.Wiley interdisciplinary reviews. RNA · 2018Review
- MicroRNAs in gynecological cancers: Small molecules with big implications.Cancer letters · 2017Review
- Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs.Non-coding RNA research · 2017Review
- MicroRNA-93-5p increases multidrug resistance in human colorectal carcinoma cells by downregulating cyclin dependent kinase inhibitor 1A gene expression.Oncology letters · 2017Article
- Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer.American journal of cancer research · 2017Review
- Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer.Journal of cancer research and clinical oncology · 2016Review
- Current state of phenolic and terpenoidal dietary factors and natural products as non-coding RNA/microRNA modulators for improved cancer therapy and prevention.Non-coding RNA research · 2016Review
- Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines.Oncology letters · 2016Article
- MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.Drug metabolism and disposition: the biological fate of chemicals · 2016Review
- The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN.Scientific reports · 2016Article
- NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis.Molecular medicine reports · 2016Article
- Role of microRNAs in chemoresistance.Annals of translational medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) have recently been identified as a novel class of gene regulators, playing an important role in various malignancies. In the present study, we investigated the role of miRNA-130b in the development of drug resistance in ovarian cancer cells. The human ovarian carcinoma cell line A2780 and paclitaxel-resistant A2780/Taxol cells were exposed to the chemotherapeutic agent cisplatin or paclitaxel in the presence or absence of transfected miR-130b. Cell viability assays were then performed using the Cell Counting Kit-8 (CCK-8) assay. Reverse transcription polymerase chain reaction and Western blotting were used to assess the messenger RNA (mRNA) and protein expression levels of glutathione S-transferase (GST)-π, multidrug resistance (MDR)1, or P-glycoprotein (P-gp). Following transfection, we found higher expression levels of miR-130b in A2780/Taxol cells than in A2780 cells (p < 0.05). Both A2780 and A2780/Taxol cells showed decreased sensitivity to paclitaxel and cisplatin compared with mock-transfected and negative control cancer cells (p < 0.05). The mRNA expression levels of MDR1 and GST-π (p < 0.05) and the protein expression levels of P-gp and GST-π were downregulated following miR-130b transfection in comparison to mock-transfected and negative control cancer cells. Our findings suggest that miRNA-130b may be involved in the development of drug resistance in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.